ReviewCurrent rheumatology reports2022
Spectrum of Spondyloarthritis Among Chinese Populations.
Review in Current rheumatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Trial
- Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.Human vaccines & immunotherapeutics · 2026Observational
- Review
- Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging.Rheumatology and therapy · 2026Article
- Multi-omics insights into spondyloarthritis and psoriatic arthritis: integrating genomics, transcriptomics, proteomics, and the microbiome for immunological and clinical translation.Frontiers in immunology · 2026Review
- Clinical efficacy of tofacitinib in active ankylosing spondylitis and dynamic changes in gut microbiota: an exploratory descriptive four-case series with 16S rRNA sequencing analysis.Frontiers in immunology · 2026Article
- Short-form video platforms as a source of ankylosing spondylitis information: a cross-sectional content analysis.Frontiers in digital health · 2026Article
- IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort.Clinical rheumatology · 2025Article
- The role and predictive value of Th17/Treg imbalance and inflammatory factors in sagittal imbalance after VCD for ankylosing spondylitis.Journal of medical biochemistry · 2025Article
- What can Animal Models tell us About T Cells in Spondyloarthritis Pathogenesis?Current rheumatology reports · 2025Review
- Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level.Rheumatology and therapy · 2025Article
- Proteomic Profiling of Inflammatory Protein Dysregulation in HLA-B27-Positive Ankylosing Spondylitis: Molecular Signatures and Potential Biomarkers.Biomolecules · 2025Article
- Analysis of sleep disorders and their influencing factors in patients with ankylosing spondylitis.PloS one · 2025Article
- Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis.Rheumatology and therapy · 2024Article
- Uncommon P1 Anchor-featured Viral T Cell Epitope Preference within HLA-A*2601 and HLA-A*0101 Individuals.ImmunoHorizons · 2024Article
- Anemia and Low Body Mass Index in Axial Spondyloarthritis: Results from ChinaSpA, the Chinese Spondyloarthritis Registry.Rheumatology and therapy · 2024Article
- Five Cases of Non-radiographic Spondyloarthritis (nr-SpA) of Patients from a Tertiary Care Center in the Philippines: A Case Series.Acta medica Philippina · 2024Article
- HLA-B*27 and Ankylosing Spondylitis: 50 Years of Insights and Discoveries.Current rheumatology reports · 2023Review
- Immune-mediated inflammatory diseases and leukocyte telomere length: A Mendelian randomization study.Frontiers in genetics · 2023Article
- Professional Creators Provide Higher-Quality Ankylosing Spondylitis Content on TikTok and Bilibili: A Cross-Sectional Study.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to emphasize interesting and important new findings with a focus on the spectrum of spondyloarthritis (SpA) in China. RECENT
findingsOver the past decade, significant advances have been made in the investigation of SpA epidemiology, the exploration of genetic and environmental risk factors, the identification of clinical features, and the updating of treatment protocols in the Chinese population. The prevalence of ankylosing spondylitis (AS) in China is 0.20-0.42%, and the prevalence of HLA-B27 in AS patients is 88.8-89.4%. HLA-B*2704 is the most common subtype in Chinese AS patients, followed by HLA-B*2705. HLA-A*01, more precisely HLA-A*01:01, may be associated with psoriatic arthritis (PsA). Tumor necrosis factor inhibitors and IL-17A inhibitors have been shown to be effective and safe for AS patients in China. Juvenile-onset AS is relatively rare, accounting for only 9.1% of the AS population. The prevalence of arthritis related to inflammatory bowel disease is 6.9 to 7.2%. A Chinese study showed that the most frequently prescribed medication was methotrexate (66.4%). Biological agents were prescribed in only16.4% of patients with PsA. This review summarizes the latest research in the epidemiology, pathogenesis, clinical manifestations, and management of SpA among Chinese populations. Multiple HLA associations with SpA have also been described, and it is hoped that discoveries of such ethnic-specific risk factor(s) and understanding of their pathological mechanisms may potentially lead to newer targeted therapies for the Chinese populations worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.